Hydroxycarbamide

BESREMi® (Ropeginterferon alfa-2B) Shows Greatest Benefit Among Cytoreductive Therapies in Lowering Symptomatic Burden of Polycythemia Vera (PV): Real-World Analysis Published at ASCO

Retrieved on: 
수요일, 5월 29, 2024
Biotechnology, Other Health, Health, Clinical Trials, Oncology, Patient, Thrombosis, Polycythemia, Phlebotomy, Diagnosis, Myeloproliferative neoplasm, NCCN, Hydroxycarbamide, Peginterferon alfa-2a, Physician, Pharming, ASCO, Journal, Society, HCP, Research, CTS, Hematology, Medicine, Medical imaging

This review included patients receiving phlebotomy alone (n=103) and each of the following cytoreductive therapies with or without concomitant phlebotomy: hydroxyurea (n=165), ruxolitinib (n=115), peginterferon alfa-2a (n=44) and ropeginterferon alfa-2b (n=45).

Key Points: 
  • This review included patients receiving phlebotomy alone (n=103) and each of the following cytoreductive therapies with or without concomitant phlebotomy: hydroxyurea (n=165), ruxolitinib (n=115), peginterferon alfa-2a (n=44) and ropeginterferon alfa-2b (n=45).
  • They observed a reduction for hydroxyurea from 7 to 4 patients (43%); in ruxolitinib from11 to 6 patients (45%), and in peginterferon alfa-2a from12 to 8 patients (33%).
  • In this review, 63% of patients were identified as high risk (>60 y/o with history of thrombosis).
  • “Polycythemia vera is a chronic blood disorder which is now recognized as a type of cancer.

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

Retrieved on: 
화요일, 5월 14, 2024
Sickle cell disease, Grady Memorial Hospital, EHA, Harvard Medical School, Hospital, Central European, Hereditary spherocytosis, Winship Cancer Institute, Abstract, University Medical Center, MMSc, All but dissertation, AGIO, American University of Beirut, Launch, Disease, Anemia, Thalassemia, Hematology, Utrecht University, University, Hydroxycarbamide, University Medical Center Utrecht, Oncology, Iron overload, American University, Pharmaceutical industry

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that data from its programs will be presented at the European Hematology Association 2024 (EHA2024) Hybrid Congress, to be held June 13-16, 2024, in Madrid, Spain.

Key Points: 
  • Additional presentations will highlight data across Agios’ pipeline in rare blood disorders, including sickle cell disease and pyruvate kinase deficiency.
  • In total, seven abstracts led by Agios and external collaborators will be presented or published.
  • The accepted abstracts are listed below and are available online on the EHA congress website at www.ehaweb.org.
  • Data from the global Phase 3 ENERGIZE study of mitapivat in alpha- or beta- non-transfusion-dependent thalassemia.

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Retrieved on: 
화요일, 1월 2, 2024
Janus, Liver, Marketing, PV, INN, Hypertension, Graft-versus-host disease, Polycythemia, Hydroxycarbamide, Infection, Transplant, Splenomegaly, Bruise, Polycythemia vera, Bacteria, Anatomy, IIA, Spleen, Fever, Hypercholesterolemia, Primary myelofibrosis, ATC, Bleeding, Disease, Ageing, JAK, Neutrophil, Blood, System, Disorder, Weight gain, Enzyme, Safety, Anemia, Sepsis, Medical Subject Headings, Agency, B cell, International, Bone pain, Neutropenia, Language, Mouth, Dizziness, Thrombocytopenia, Pancreatic serous cystadenoma, Hypertriglyceridemia, Tablet, Select, Patient, Medicine, Phlebotomy, Hormone, Woman, Weight loss, Headache, Cytomegalovirus, European Medicines Agency, Growth, Janus kinase, Urinary tract infection, Medical device

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 29, Status: Authorised

Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH

Retrieved on: 
월요일, 12월 11, 2023
CRS, CYP, NPM1, Hematopoietic stem cell transplantation, Level 4, Arm, MEN1, ITGAM, Plasma, MEIS1, Society, DS, Hydroxycarbamide, ASH, Postcholecystectomy syndrome, Mutation, Steroid, DSM-IV codes, ANPEP, Gene expression, CD14, Cancer, Poster, Toxicity, HSCT, Patient, AUC, AML, Osteopathic medicine in Canada, Pharmaceutical industry

Pharmacodynamic data from a case study of an AML patient containing NUP98-NSD1 mutation showed suppression of key leukemogenic genes (e.g.

Key Points: 
  • Pharmacodynamic data from a case study of an AML patient containing NUP98-NSD1 mutation showed suppression of key leukemogenic genes (e.g.
  • Initially, patients were enrolled agnostic to mutational status; subsequently, the study protocol was amended to enrich for patients with AML harboring menin-dependent mutations.
  • Biomea is planning to amend the dosing protocol to explore higher dosing levels in Arm B.
  • Dose escalation is to be followed by a dose optimization/expansion to determine the recommended phase 2 dose.

Live from ASH 2023 | Results from Chinese Studies of Olverembatinib Presented in Oral Report at the ASH Annual Meeting for the Sixth Consecutive Year, Including Data Showing Promising Efficacy in Patients with TKI-Resistant and/or Intolerant CML-CP

Retrieved on: 
수요일, 12월 13, 2023
Hydroxycarbamide, Research, Intolerance, Dasatinib, HHT, Aes, Incidence, ASH, Risk, NMPA, TKI, Eastern Cooperative Oncology Group, Hematology, Disease, Hospital, Patient, Nilotinib, QOD, Pacific Time Zone, BCR, Pacific Ocean, CHB, Prognosis, Natural product, ECOG, Cancer, CML, Death, R, Hepatitis, Society, Notifiable disease, BAT, HIV disease progression rates, Pharmaceutical industry, Nursing, EFS

This is the sixth consecutive year in which study results on olverembatinib have been selected for Oral Presentations at the ASH Annual Meeting.

Key Points: 
  • This is the sixth consecutive year in which study results on olverembatinib have been selected for Oral Presentations at the ASH Annual Meeting.
  • After reaching EFS, patients in the BAT arm were allowed to cross-over to the olverembatinib arm for continued treatment.
  • Patients: As of October 17, 2023, a total of 144 patients were enrolled, of whom 96 patients received olverembatinib and 48 received BAT.
  • In addition, the olverembatinib arm has shown a higher cumulative response rate and longer duration of responses.

SIKLOS® (hydroxyurea) is now covered by State Medicaid programs in 19 states

Retrieved on: 
목요일, 9월 21, 2023
Infection, Bleeding, Use, Medication, HIV, Urine, Pharmacy, Hydroxycarbamide, Chills, Breast milk, Fever, Skin cancer, Cancer, History, Life expectancy, Macrocytosis, USP, Government, Gangrene, Tablet, SCA, Vitamin, Capsule, Bruise, Jaundice, Patient, Anti-transglutaminase antibodies, Risk, Folate, Blood, Boxed warning, Water, Disease, Leukemia, FDA, Headache, Hemolytic anemia, Death, Glass, Skin, Female, Full, Health insurance, Dietary supplement, Vaccine, Pharmaceutical industry, Personal protective equipment, Birth control

“Since launching Siklos® five years ago, Medunik USA has been focusing its efforts on easing access to this valuable treatment option which is now covered by State Medicaid programs in 19 states,” said Tanya Carro, Executive Vice-President of Medunik USA.

Key Points: 
  • “Since launching Siklos® five years ago, Medunik USA has been focusing its efforts on easing access to this valuable treatment option which is now covered by State Medicaid programs in 19 states,” said Tanya Carro, Executive Vice-President of Medunik USA.
  • Most of those affected are of African ancestry; a minority are of Hispanic or southern European, Middle Eastern or Asian Indian descent3.
  • Your healthcare provider will check your blood cell counts before and every 2 weeks during treatment with SIKLOS®.
  • Your healthcare provider may do blood tests if you have persistent or worsening anemia not related to sickle cell anemia.

Scene Health & The Research Institute at Nationwide Children’s Hospital Secure $1.9M in NIH Funding to Pursue Improvements in Sickle Cell Disease Care and Outcomes

Retrieved on: 
화요일, 9월 19, 2023
Technology, Biotechnology, Audio, Video, Health, Consumer, Apps, Applications, Pharmaceutical, Research, Teens, Software, Children, Hospitals, Science, Clinical Trials, Partnership, Nationwide Children's Hospital, SBIR, Scene, SCD, National Heart, Lung, and Blood Institute, End organ damage, Quality of life, Small Business Innovation Research, Medicine, Cell, Lung, Pain, DOT, Patient, Sickle cell disease, Research institute, Hospital, Caregiver, Nationwide, Birth control, Hydroxycarbamide

Sickle cell disease hurts, and the debilitating pain can send children to the hospital multiple times a year.

Key Points: 
  • Sickle cell disease hurts, and the debilitating pain can send children to the hospital multiple times a year.
  • Today, Scene Health and the Research Institute at Nationwide Children's Hospital announced a $1.9 million effort to help children and teenagers living with sickle cell disease (SCD) improve their health and quality of life through increased adherence to hydroxyurea treatment.
  • The Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute will fund the ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness) study.
  • With Scene's collaboration, the ADHERE study is poised to optimize video DOT's ability to promote lasting adherence.

Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera Published in Medical Journal Leukemia

Retrieved on: 
화요일, 9월 19, 2023
Science, Research, Pharmaceutical, Finance, Oncology, General Health, Health, Professional Services, BAT, Civil service commission, Polycythemia vera, European Hematology Association, Hydroxycarbamide, Medical school, Multimedia, Ropeginterferon alfa-2b, H, Patient, Titan IIIB, AOP, Annual general meeting, Medical University of Vienna, Paper, ATC, Polycythemia, Leukemia, European Commission, Safety, Disease, Pharmaceutical industry, PV

AOP Orphan Pharmaceuticals GmbH (AOP Health) announced the publication of final results on the recently developed interferon therapy, ropeginterferon alfa-2b, in patients with polycythemia vera (PV) in the prestigious journal Leukemia1.

Key Points: 
  • AOP Orphan Pharmaceuticals GmbH (AOP Health) announced the publication of final results on the recently developed interferon therapy, ropeginterferon alfa-2b, in patients with polycythemia vera (PV) in the prestigious journal Leukemia1.
  • The full publication expands on results presented at the Annual Meeting of the European Hematology Association.
  • Results of long-term treatment in the CONTINUATION-PV study provide further evidence of the disease modifying capacity of ropeginterferon alfa-2b in PV.
  • Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology

Retrieved on: 
수요일, 8월 30, 2023
GSK plc, Disease, Headache, Essential thrombocythemia, Bleeding, Prevalence, Conditional sentence, Hydroxycarbamide, Bone marrow, Genetic testing, Platelet, Petechia, Aspirin, Common, LAS, Bruise, Dizziness, Spleen, Novartis, Patient, Risk, Physiology, Plateletpheresis, Blood, MMB, CTI, Thrombocythemia, United Kingdom, Abdomen, Diagnosis, Oncology, Haematopoietic system, Skin, Medical device, Medical imaging, Pacritinib, Momelotinib, Ropeginterferon alfa-2b

LAS VEGAS, Aug. 30, 2023 /PRNewswire/ -- DelveInsight's Essential Thrombocythemia Market Insights report includes a comprehensive understanding of current treatment practices, essential thrombocythemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • These factors along with the expected launch of emerging therapies will boost the essential thrombocythemia market in the forecasted period.
  • As per DelveInsight analysts, total prevalent population of essential thrombocythemia in the 7MM was 240K in 2020.
  • Estimates observed that the age-group 60-80 years accounted for highest cases of essential thrombocythemia in the United States.
  • To know more about essential thrombocythemia treatment, visit @ Essential Thrombocythemia Treatment Drugs

Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology

Retrieved on: 
수요일, 8월 30, 2023
GSK plc, Disease, Headache, Essential thrombocythemia, Bleeding, Prevalence, Conditional sentence, Hydroxycarbamide, Bone marrow, Genetic testing, Platelet, Petechia, Aspirin, Common, LAS, Bruise, Dizziness, Spleen, Novartis, Patient, Risk, Physiology, Plateletpheresis, Blood, MMB, CTI, Thrombocythemia, United Kingdom, Abdomen, Diagnosis, Oncology, Haematopoietic system, Skin, Medical device, Medical imaging, Pacritinib, Momelotinib, Ropeginterferon alfa-2b

LAS VEGAS, Aug. 30, 2023 /PRNewswire/ -- DelveInsight's Essential Thrombocythemia Market Insights report includes a comprehensive understanding of current treatment practices, essential thrombocythemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • These factors along with the expected launch of emerging therapies will boost the essential thrombocythemia market in the forecasted period.
  • As per DelveInsight analysts, total prevalent population of essential thrombocythemia in the 7MM was 240K in 2020.
  • Estimates observed that the age-group 60-80 years accounted for highest cases of essential thrombocythemia in the United States.
  • To know more about essential thrombocythemia treatment, visit @ Essential Thrombocythemia Treatment Drugs